Business
Innovation Pharmaceuticals Provides a Comparative Perspective on Brilacidin’s Potential to Unlock the Oral Mucositis Market: Pharma Industry Attacks Severe Pain and Suffering Due to Cancer Treatments
Innovation Pharmaceuticals Provides a Comparative Perspective on Brilacidin’s Potential to Unlock the Oral Mucositis Market: Pharma Industry Attacks Severe Pain and Suffering Due to Cancer Treatments.
About this update from Innovation Pharmaceuticals Inc.
[{"type":"text","content":"\nBEVERLY, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide a comparative perspective on the development of Brilacidin for the prevention of severe Oral Mucositis (SOM) in Head and Neck Cancer (HNC). The late-stage drug candidate, one of the few drugs currently in clinical development shown to reduce the incidence of SOM, further advantaged by its convenient mode of administration as an oral rinse, is emerging as clearly differentiated and highly promising.\n Linked below is information, published in a blog on the Company’s website, elaborating on how Brilacidin is favorably positioned compared to other investigational Oral Mucositis (OM) drugs currently in clinical development. “Brilacidin for Oral Mucositis: At-a-Glance Comparative Data Presentation with Other Investigational OM Drugs” http://www.ipharminc.com/new-blog/2018/9/24/brilacidin-for-oral-mucositis-at-a-glance-comparative-data-presentation-with-other-investigational-om-drugs The Market Opportunity and Unmet Need in Oral Mucositis Various drug companies in the OM space are conducting mid-and-late-stage clinical trials, with one private company recently raising $150 million to fund further development of its OM drug candidate. We believe the magnitude of such a sizable investment commitment confirms our own assessment that an effective drug to prevent—or even reduce the duration of SOM—has the potential to capture a substantial new market. OM represents a large unmet medical need and is estimated to be a $1 billion market opportunity, increasingly garnering substantial pharmaceutical industry interest. Patients desperately await effective OM treatments, as relayed in a video on the painful and debilitating side-effects of the condition published on the “Healthy Body, Healthy Mind” website. “The results of the Brilacidin OM Phase 2 are compelling,” said Company Scientific Advisor and OM expert, Stephen T. Sonis, DMD, DMSc, of Brigham and Women's Hospital. “The lack of preventive or definitive treatment options for patients at risk of, or suffering from, OM is a consistent source of patient misery and leads to costly and clinically significant downstream consequences. I enthusiastically...